Research progress in the role of CD38 in clinical tumor treatment

Tumor is one of the ten leading causes of death in the world. Traditional tumor treatments include surgery, radiation therapy, and chemotherapy. With the development of immune checkpoint blockade therapy targeting the programmed death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis, the number...

Full description

Saved in:
Bibliographic Details
Published in:Zhong nan da xue xue bao. Journal of Central South University. Yi xue ban 2022-07, Vol.47 (7), p.952-959
Main Authors: He, Zhengxi, Liu, Xing, Zhou, Yanhong
Format: Article
Language:chi ; eng
Subjects:
B7-H1 Antigen - metabolism
Combined Modality Therapy
Humans
Immunotherapy
Neoplasms - therapy
Programmed Cell Death 1 Receptor - metabolism
Tumor Microenvironment
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor is one of the ten leading causes of death in the world. Traditional tumor treatments include surgery, radiation therapy, and chemotherapy. With the development of immune checkpoint blockade therapy targeting the programmed death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis, the number of cancers in solid tumors has increased. Changes in the immunometabolic microenvironment have been shown to be important regulators of innate suppression of immune cell function and acquired resistance to immunotherapy. As a new target, CD38 is an enzyme that produces immunosuppressive metabolites (such as adenosine), which can be used in combination with immunotherapy to improve the clinical efficacy of tumor therapy, and can also be used as an indicator for understanding tumor immunotherapy response.
ISSN:1672-7347
DOI:10.11817/j.issn.1672-7347.2022.210351